The DOI matches its Crossref record.
The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time*
Abstract
Methylnaltrexone is a quaternary opioid antagonist with limited ability to cross the blood-brain barrier that has the potential to antagonize the peripherally mediated gastrointestinal effects of opioids. In recent trials in human volunteers, we demonstrated that intravenous methylnaltrexone prevented morphine-induced changes in gastrointestinal motility and transit, without affecting analgesia. In this study, 14 healthy volunteers were first given three ascending oral doses of methylnaltrexone to obtain safety and tolerance data (phase A study). In phase B, these subjects were then given single-blind oral placebo and intravenous placebo, followed by randomized, double-blind oral placebo and intravenous morphine (0.05 mg/kg) or oral methylnaltrexone (19.2 mg/kg, an established highest and safe dose based on previous administrations of two smaller doses of 0.64 mg/kg and 6.4 mg/kg in phase A) and intravenous morphine (0.05 mg/kg). Oral-cecal transit time was assessed by the pulmonary hydrogen measurement technique after lactulose ingestion. Morphine significantly increased oral-cecal transit time from 114.6 +/- 37.0 minutes (mean +/- SD) to 158.6 +/- 50.2 minutes (p < 0.001). Oral methylnaltrexone (19.2 mg/kg) completely prevented morphine-induced increase in oral-cecal transit time (110.4 +/- 45.0 minutes; not significant compared with baseline; p < 0.005 compared with morphine alone). These sessions were then followed by single-blind evaluations of descending doses of methylnaltrexone. We observed that 6.4 mg/kg oral methylnaltrexone significantly attenuated the morphine-induced delay in oral-cecal transit time (p < 0.005 compared with morphine alone), and a dose-dependent response was obtained. There was no correlation between oral methylnaltrexone effects on the transit time and the drug plasma concentration, suggesting direct preferential luminal effects of oral methylnaltrexone. Oral methylnaltrexone may have a clinical value in the prevention and treatment of constipation induced by long-term opioid use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness
Thomas, J., Karver, S., Cooney, G. A., Chamberlain, B. H., Watt, C. K., Slatkin, N. E., Stambler, N., Kremer, A. B., & Israel, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707377 · Cited by 595
Opioid-Induced Bowel Dysfunction: Pathophysiology and Potential New Therapies
Kurz, A., & Sessler, D. I. (2003) · Drugs · doi:10.2165/00003495-200363070-00003 · Cited by 587
Incidence, Prevalence, and Management of Opioid Bowel Dysfunction
Pappagallo, M. (2001) · The American Journal of Surgery · doi:10.1016/s0002-9610(01)00782-6 · Cited by 531
Yuan, C.-S., Foss, J. F., O'Connor, M., Osinski, J., Karrison, T., Moss, J., & Roizen, M. F. (2000) · JAMA · doi:10.1001/jama.283.3.367 · Cited by 297
Self-citationOpioid-Induced Constipation: Challenges and Therapeutic Opportunities
Camilleri, M. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.30 · Cited by 262
Metadata
- Authors
- Yuan, C.-S., Foss, J. F., Osinski, J., Toledano, A., Roizen, M. F., & Moss, J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1997-04
- Volume
- 61
- Issue
- 4
- Pages
- 467-475
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2022477506
- Cited by
- 169
- References
- 0
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time*. https://app.cochat.ai/papers/10.1016/s0009-9236(97)90197-1
- The paper
- Yuan, C.-S., Foss, J. F., Osinski, J., Toledano, A., Roizen, M. F., & Moss, J. (1997). The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time*. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/s0009-9236(97)90197-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.